

7 July 2021

Further Success with NTI's Preclinical Testing Program - Multiple Sclerosis Models

Highlights:

- Recently completed preclinical studies targeting potential MS treatments has demonstrated that NTI/Dolce cannabis strains can suppress and inhibit the expression of COX-2 in human derived microglial cells.
- When compared to CBD alone, NTI/Dolce strains were up to three times more powerful in suppressing COX-2 both pre and post inflammatory insult.

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to announce further success of its in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary NTI/Dolce cannabis leads.

Neurotech has been undertaking a series of preclinical studies to assess the neuroprotective, anti-inflammatory and neuro-modulatory activities of the proprietary NTI/Dolce cannabis leads CBDA, CBDP, CBDB all with less than 0.3% THC. These studies have been conducted at three leading independent laboratories – Monash University, University of Wollongong and RMIT University.

Multiple Sclerosis (MS) is a progressive inflammatory disease characterised by the loss of myelin sheath within the central nervous system. Typical symptoms include fatigue, walking difficulties and impaired speech and vision. Cyclooxygenase-2 (COX-2) is considered the main enzyme responsible for causing inflammation, the common mechanism of disease involved in MS. COX-2 is a powerful clinical biomarker in the assessment of disease progression and overall therapeutic management.

Preclinical studies targeting potential MS treatments has demonstrated that NTI/Dolce cannabis strains can suppress and inhibit the expression of COX-2 in human derived microglial cells. When compared to CBD alone, NTI/Dolce strains were up to three times more powerful in suppressing COX-2 both pre and post inflammatory insult (refer table below).

N	Control Avg	DOLCE/NTI	CBD Avg	Positive control vs DOLCE/NTI treatment	Positive control vs CBD alone treatment
<i>Pre-Inflammatory Exposure (exposure 1 hour prior to inflammatory insult)</i>					
9	94.47 +/- 5.90 (SEM)	53.67 +/- 6.41 (SEM)	84.82 +/- 7.65 (SEM)	P = 0.0003	P = 0.3237
<i>Pre-Inflammatory Exposure (exposure 1 hour after inflammatory insult)</i>					
9	104.26 +/- 11.08 (SEM)	21.10 +/- 6.82 (SEM)	76.32 +/- 7.95 (SEM)	P <0.0001	P = 0.0566
- NTI/Dolce is more potent than CBD alone in suppressing COX-2 expression in human microglial cells. - DAPI cell viability stain: No cell death was detected and assessed as per the DAPI cell staining method. - Cells were viable throughout these in vitro studies. - Positive control/ Inflammatory activation: Interleukin and Interferon gamma					

Therapies that are able to inhibit COX-2 provide promise in the overall management of MS. Studies published by various international groups[^] confirm that COX-2 plays an important role in the progression of MS and adjunct therapies such as Non-Steroidal Anti-inflammatory Drugs (NSAIDs) can reduce fatigue and improve cognitive abilities. Next stage pre-clinical studies will compare

NTI/Dolce strains against current pharmaceutical treatment options which have multiple long term use side effect implications. These studies are expected to be completed in July and initiation of Phase II clinical trials in Q1 next calendar year.

“These results re-confirm the potent anti-inflammatory properties of NTI/Dolce strains and provide further evidence for their development as neuro anti-inflammatory therapies across a number of neuro diseases,” said Brian Leedman, Chairman of Neurotech International. “With our Phase I/II clinical studies into the treatment of Autistic children approaching the half way point, NTI is looking forward to delivering an exciting second half in this calendar year”.

This announcement has been authorised for release by the Board of Directors of Neurotech International Limited

Further Information

Brian Leedman
Chairman
b.leedman@neurotechinternational.com
+61 (0)41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 (0)41 066 7844

About Neurotech

Neurotech International Limited is a medicinal cannabis company conducting clinical studies to assess the neuroprotective, anti-inflammatory and neuro-modulatory activities of our proprietary DOLCE/NTI cannabis strains which include CBDA, CBDP and CBDB. The licensed strains contain < 0.3% THC potentially providing a clearer pathway to regulatory approval than all other cannabis companies that contain far higher THC levels. Neurotech is also commercialising Mente, the world's first home therapy clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism, please visit:

<http://www.neurotechinternational.com>